Home > Insider Trading > Filing (0001179110-12-007828)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1356576	Supernus Pharmaceuticals Inc	SUPN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1283887	B Michael Sheffery	C/O Orbimed Advisors Llc, 601 Lexington Avenue, 54Th Floor New York NY 10022		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-05-04	1,668,472	$0.00	1,668,472	No	4	C	Indirect	By OrbiMed Private Investments II, LP
Common Stock	Acquisiton	2012-05-04	624,710	$0.00	624,710	No	4	C	Indirect	By OrbiMed Private Investments II (QP), LP
Common Stock	Acquisiton	2012-05-04	206,816	$0.00	206,816	No	4	C	Indirect	By UBS Juniper Crossover Fund, L.L.C.
Common Stock	Acquisiton	2012-05-04	734,128	$5.00	2,402,600	No	4	P	Indirect	by OrbiMed Private Investments II LP
Common Stock	Acquisiton	2012-05-04	274,873	$5.00	899,583	No	4	P	Indirect	By OrbiMed Private Investments II (QP), LP
Common Stock	Acquisiton	2012-05-04	90,999	$5.00	297,815	No	4	P	Indirect	By UBS Juniper Crossover Fund, L.L.C

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By OrbiMed Private Investments II, LP
No	4	C	Indirect	By OrbiMed Private Investments II (QP), LP
No	4	C	Indirect	By UBS Juniper Crossover Fund, L.L.C.
No	4	P	Indirect	by OrbiMed Private Investments II LP
No	4	P	Indirect	By OrbiMed Private Investments II (QP), LP
No	4	P	Indirect	By UBS Juniper Crossover Fund, L.L.C

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2012-05-04	6,673,891	$0.00	1,668,472	$0.00
Common Stock	Series A Preferred Stock	Disposition	2012-05-04	2,498,842	$0.00	624,710	$0.00
Common Stock	Series A Preferred Stock	Disposition	2012-05-04	827,627	$0.00	206,816	$0.00

Exercise Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2005-12-22	No	4	C	Indirect
2005-12-22	No	4	C	Indirect
2005-12-22	No	4	C	Indirect

Footnotes

Each share of Series A Preferred Stock automatically converted into 0.25 shares of Common Stock (together the shares of Series A Preferred Stock and the shares of Common Stock, the "Shares") without payment of consideration upon the closing of the Issuer's initial public offering. Any fractional shares upon the conversion were paid out in cash. The shares of Series A Preferred Stock do not have an expiration date.
Mr. Sheffery is a member of OrbiMed Advisors LLC, the managing member of OrbiMed Capital GP II LLC, which is the general partner of OrbiMed Private Investments II, LP and OrbiMed Private Investments II (QP), LP. Investment professionals employed by OrbiMed Advisors LLC manage UBS Juniper Crossover Fund, L.L.C.'s investment portfolio on behalf of UBS Juniper Management, L.L.C. Mr. Sheffery disclaims beneficial ownership of the Shares and this report shall not be deemed an admission that such reporting person is the beneficial owner of such Shares, except to the extent of his pecuniary interest, if any, in the Shares by virtue of his interest in OrbiMed Advisors LLC.